MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Cho, Shih Feng ^a,b   Chang, Yuli Christine ^b   Chang, Chao Sung ^b,c   Lin, Sheng Fung ^a,b   Liu, Yi Chang ^a,b   Hsiao, Hui Hua ^a,b   Chang, Jan Gowth ^d,e   Liu, Ta Chih ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Long non coding RNA; Metastasis associated lung adenocarcinoma transcript 1 (MALAT1); Multiple myeloma

Indexed keywords

LONG UNTRANSLATED RNA; TUMOR MARKER; MALAT1 LONG NON-CODING RNA, HUMAN;

ADULT; ARTICLE; BONE MARROW DERIVED MONONUCLEAR CELL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; MALAT1 GENE; MALE; MULTIPLE MYELOMA; PREDICTION; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AGED; BONE MARROW; DISEASE COURSE; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENETICS; MIDDLE AGED; MONONUCLEAR CELL; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE; TIME;

AGED; BONE MARROW; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; RNA, LONG NONCODING; ROC CURVE; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84920857083     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-809     Document Type: Article

References (32)

1. Palumbo A, Anderson K: Multiple myeloma. N Engl J Med 2011, 364:1046-1060.
2. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM: A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009, 113:5418-5422.
3. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV: Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009, 113:5412-5417.
4. Kuehl WM, Bergsagel PL: Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002, 2:175-187.
5. Seidl S, Kaufmann H, Drach J: New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003, 4:557-564.
6. Bergsagel PL, Kuehl WM: Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005, 23:6333-6338.
7. Morgan GJ, Walker BA, Davies FE: The genetic architecture of multiple myeloma. Nat Rev Cancer 2012, 12:335-348.
8. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, Rajkumar SV: Expression of VEGF and its receptors by myeloma cells. Leukemia 2003, 17:2025-2031.
9. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI: Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004, 103:3503-3510.
10. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC: Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007, 7:585-598.
11. Bertone P, Stolc V, Royce TE, Rozowsky JS, Urban AE, Zhu X, Rinn JL, Tongprasit W, Samanta M, Weissman S, Gerstein M, Snyder M: Global identification of human transcribed sequences with genome tiling arrays. Science 2004, 306:2242-2246.
12. International Human Genome Sequencing C: Finishing the euchromatic sequence of the human genome. Nature 2004, 431:931-945.
13. Hauptman N, Glavac D: Long non-coding RNA in cancer. Int J Mol Sci 2013, 14:4655-4669.
14. Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, BerdelWE, Serve H, Muller-Tidow C: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003, 22:8031-8041.
15. Guru SC, Agarwal SK, Manickam P, Olufemi SE, Crabtree JS, Weisemann JM, Kester MB, Kim YS, Wang Y, Emmert-Buck MR, Liotta LA, Spiegel AM, Boguski MS, Roe BA, Collins FS, Marx SJ, Burns L, Chandrasekharappa SC: A transcript map for the 2.8-Mb region containing the multiple endocrine neoplasia type 1 locus. Genome Res 1997, 7:725-735.
16. van Asseldonk M, Schepens M, de Bruijn D, Janssen B, Merkx G, Geurts van Kessel A: Construction of a 350-kb sequence-ready 11q13 cosmid contig encompassing the markers D11S4933 and D11S546: mapping of 11 genes and 3 tumor-associated translocation breakpoints. Genomics 2000, 66:35-42.
17. Wilusz JE, Freier SM, Spector DL: 3' end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell 2008, 135:919-932.
18. Friedel CC, Dolken L, Ruzsics Z, Koszinowski UH, Zimmer R: Conserved principles of mammalian transcriptional regulation revealed by RNA half-life. Nucleic Acids Res 2009, 37:e115.
19. Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, Chess A: A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics 2007, 8:39.
20. Miyagawa R, Tano K, Mizuno R, Nakamura Y, Ijiri K, Rakwal R, Shibato J, Masuo Y, Mayeda A, Hirose T, Akimitsu N: Identification of cis-and trans-acting factors involved in the localization of MALAT-1 noncoding RNA to nuclear speckles. RNA 2012, 18:738-751.
21. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, Blencowe BJ, Prasanth SG, Prasanth KV: The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 2010, 39:925-938.
22. Yang F, Yi F, Han X, Du Q, Liang Z: MALAT-1 interacts with hnRNP C in cell cycle regulation. FEBS Lett 2013, 587:3175-3181.
23. Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, Zhang Y, Gorospe M, Prasanth SG, Lal A, Prasanth KV: Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet 2013, 9:e1003368.
24. Schmidt LH, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D, Marra A, Hillejan L, Wiebe K, Berdel WE, Wiewrodt R, Muller-Tidow C: The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol 2011, 6:1984-1992.
25. Xu C, Yang M, Tian J, Wang X, Li Z: MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis. Int J Oncol 2011, 39:169-175.
26. Ying L, Chen Q, Wang Y, Zhou Z, Huang Y, Qiu F: Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-tomesenchymal transition. Mol Biosyst 2012, 8:2289-2294.
27. Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zornig M, MacLeod AR, Spector DL, Diederichs S: The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 2013, 73:1180-1189.
28. Lane L, Argoud-Puy G, Britan A, Cusin I, Duek PD, Evalet O, Gateau A, Gaudet P, Gleizes A, Masselot A, Zwahlen C, Bairoch A: neXtProt: a knowledge platform for human proteins. Nucleic Acids Res 2012, 40:D76-83.
29. Wu C, Macleod I, Su AI: BioGPS and MyGene.info: organizing online, gene-centric information. Nucleic Acids Res 2013, 41:D561-565.
30. Isin M, Ozgur E, Cetin G, Erten N, Aktan M, Gezer U, Dalay N: Investigation of circulating lncRNAs in B-cell neoplasms. Clin Chim Acta 2014, 431:255-259.
31. Chanan-Khan AA, Giralt S: Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010, 28:2612-2624.
32. Moreau P, Attal M, Pegourie B, Planche L, Hulin C, Facon T, Stoppa AM, Fuzibet JG, Grosbois B, Doyen C, Ketterer N, Sebban C, Kolb B, Chaleteix C, Dib M, Voillat L, Fontan J, Garderet L, Jaubert J, Mathiot C, Esseltine D, Avet-Loiseau H, Harousseau JL, investigators IFMs: Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 2011, 117:3041-3044.